Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer

Figures & data

Table 1. Patient characterization.

	Cohort 1	Cohort 2	All	p Value
Number of patients, n	26	21	47
Age (year)				.9
Median	49	48	47
Range	31–63	31–66	31–66
Histopathology				.1
Ductal	19 (73)^a	18 (86)	37 (79)
Lobular	3 (12)	1 (5)	4 (9)
Other	4 (15)	0 (0)	4 (9)
Unknown	0 (0)	2 (9)	2 (4)
ER status				.2
Pos	10 (38)	12 (57)	22 (47)
Neg	16 (62)	9 (43)	25 (53)
HER-2 status				.02
Normal	11 (42)	16 (76)	27 (58)
Pos	14 (54)	3 (14)	17 (36)
Unknown	1 (4)	2 (10)	3 (6)
Triple negative status				.6
Yes	7 (27)	7 (33)	14 (30)
No	19 (73)	14 (67)	33 (70)
Grade of anaplasia				.4
1	3 (12)	1 (5)	4 (9)
2	4 (15)	7 (33)	11 (23)
3	14 (54)	8 (38)	22 (47)
Unknown	5 (19)	5 (24)	10 (21)
Lines of palliative treatments				.2
0–1	2 (8)	5 (24)	7 (15)
2–4	13 (50)	12 (57)	25 (53)
5–7	7 (27)	2 (10)	9 (19)
8–10	4 (15)	2 (10)	6 (13)
Overall relapse duration (month)				.01
Median (CI)	28.3 (18.4;43.7)	9.5 (4.2;21.4)	17.4 (11.2;27.2)
Range	0.9–129.2	0.3–114.8	0.3–129.2
PS (WHO)				.1
0	12 (46)	6 (29)	18 (38)
1–2	12 (46)	15 (71)	27 (58)
3–4	2 (8)	0 (0)	2 (4)
Metastatic sites				.8
1	1(4)	2 (10)	3 (6)
2–3	15 (58)	12 (57)	27 (58)
4–5	10 (38)	7 (33)	17 (36)

Age (year): age at the time of primary diagnosis. Lines of previous treatments: the number of lines of systemic antineoplastic treatment (chemotherapy and/or anti-hormonal therapy) the patient has been exposed to before carboplatin treatment. Overall relapse duration (month): describes the patients’ overall duration of time of the disease from first relapse to the start of carboplatin treatment. PS: Performance status at the start of carboplatin treatment. Metastatic sites: metastatic sites at the start of carboplatin treatment.

^a Percent values in brackets.

Table 2. Response to therapy.

	Cohort 1	Cohort 2	All
Time to progression (month)
All
Median (CI)	2.3 (1.7;3.2)	4.1 (2.4;4.7)	2.8 (1.9;3.9)
Range	0.4–19.3	1.2–14.5	0.4–19.3
5–7 lines
Median (CI)	3.1 (1.9;9.6)	5.0 (5.0; .)	4.4 (1.9;9.6)
Range	1.9;19.3	5.0;9.1	1.9;19.3
8–10 lines
Median (CI)	7.0(1.8; .)	2.8(2.8; .)	4.4(1.8; .)
Range	1.8;8.5	2.8;4.4	1.8;8.5
Time to response (weeks)
Median (CI)	6.1 (3.0;7.6)	8.9 (6.1;11.6)	7.6 (4.1;8.9)
Range	3.0–8.4	6.1–12.9	3.0–12.9
Best tumor response, n (%)
CR	1 (4)^a	2 (10)	3 (6)
PR	6 (23)	6 (29)	12 (26)
SD	5 (19)	4 (19)	9 (19)
PD	11 (42)	7 (33)	18 (38)
Unknown	3 (12)	2 (10)	5 (11)
Objective response rate % (CI)
All	26.9 (11.6;47.8)	38.1 (18.1;61.6)	31.9 (19.1;47.1)
5–7 lines	28.6 (3.7;71.0)	50.0 (1.3;98.7)	33.3 (7.5;70.1)
8–10 lines	50.0(6.8;93.2)	0.0(0.0;84.2)	33.3 (4.3;77.7)
Clinical benefit rate % (CI)	46.2 (26.6;66.6)	57.1 (34.0;78.2)	51.1 (36.1;65.9)
Time to death (month)
Median (CI)	8.8 (5.3;13.7)	8.2 (6.2;13.4)	8.8 (6.8;11.0)
Range	0.4–54.2	1.7–26.0	0.4–54.2

5–7 lines: women pretreated with 5–7 lines of systemic antineoplastic treatment.

8–10 lines: women pretreated with 8–10 lines of systemic antineoplastic treatment.

^a Percent values in brackets.